Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965569 | 0.85 | PDE7A (0.57) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2960330 | 0.84 | ALDH1A1 (0.69) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2016083 | 0.83 | ALDH1A1 (0.67) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2960341 | 0.83 | PDE7A (0.67) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2016906 | 0.81 | PDE7A (0.68) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2023299 | 0.81 | PDE7A (0.68) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2961914 | 0.81 | ALDH1A1 (0.56) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2961786 | 0.80 | PDE7A (0.74) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2968600 | 0.80 | PDE7A (0.62) | PDE7AKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL29780387 | 0.79 | PDE7A (0.82) | PDE7AKMT2AMEN1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | claimed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | claimed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | claimed |
| EP-1893618-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-05 | — | — | EP | claimed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | claimed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | PDE7A 3826/4885KMT2A 2418/4885MEN1 4735/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | PDE7A 3960/4885KMT2A 2644/4885MEN1 4691/4885 |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885KMT2A 3566/4885MEN1 4571/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | PDE7A 4223/4885KMT2A 3566/4885MEN1 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.